✦ LIBER ✦

Long-term results of thalidomide and dexamethasone (thal–dex) as therapy of first relapse in multiple myeloma

✍ Scribed by Elena Zamagni; Alessandro Petrucci; Patrizia Tosi; Paola Tacchetti; Giulia Perrone; Annamaria Brioli; Lucia Pantani; Beatrice Zannetti; Carolina Terragna; Michele Baccarani; Michele Cavo

Book ID: 105989950
Publisher: Springer
Year: 2011
Tongue: English
Weight: 257 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1320-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term results of single-agent thalid

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

✍ Kristen Detweiler-Short; Suzanne Hayman; Morie A. Gertz; Martha Q. Lacy; Angela 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB 👁 1 views

Long-term thalidomide therapy resulted i

Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma

✍ Hus, M; Dmoszyñska, A; Kocki, J; Hus, I; Jawniak, D; Adamczyk-Cioch, M; Grzasko, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 99 KB

Bortezomib, thalidomide, dexamethasone i

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)

✍ Hyeon-Seok Eom; Yeo-Kyeoung Kim; Joo-Seop Chung; Kihyun Kim; Hyo Jung Kim; Ho Yo 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 153 KB

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

Long-term follow-up on overall survival

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

✍ Dimopoulos, M A; Chen, C; Spencer, A; Niesvizky, R; Attal, M; Stadtmauer, E A; P 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 164 KB